David Hallas (CEO) and Chris Wilks (CFO) of ECO Animal Health conducted a live presentation covering the company's Full-Year Interim Results for the period to 31 March. Highlights included a 10% increase in Group Revenue, and Gross Margins rising to 48.6% (FY 2025: 45.1%), driven by growth in higher-margin markets.
The team discussed the launch of ECOVAXXIN MS in Europe, the cautious outlook for China and the R&D growth pipeline. They also provided a detailed financial and operational review and the outlook for ECO, while answering a range of questions submitted by viewers.
